Submissions flow into review of insurance discrimination
More than 1000 submissions have been made to the Federal Government’s review of laws around the use of consumers’ genetic test results by life insurance companies.
On this page, you will find current research and news relating to genomics and genomic testing: explore here if you are interested in new research or advances in the area of genomics.
More than 1000 submissions have been made to the Federal Government’s review of laws around the use of consumers’ genetic test results by life insurance companies.
Australian Genomics developed a report for the Medical Research Future Fund, detailing priorities for pharmacogenomics research going forward.
A major study into the meaningful involvement of community members in genomic research has culminated in the publication of a comprehensive set of guidelines for researchers
National legislation is required to protect people against life insurance discrimination based on their genetic results.
A suite of best-practice tools developed by GeneEQUAL will support health professionals to provide inclusive, person-centred and respectful genetic health care for people with intellectual disability.
CTRL is a convenient, web-based tool created by Australian Genomics which gives research participants more control over their consent preferences when involved in a study. Read more about CTRL and the principles of dynamic consent here.
Rapid genomic testing is transforming medical care – particularly the diagnosis of people with rare conditions. For some critically ill children, rapid genomic testing can even be lifesaving.
Queensland Genomics have produced a Genomics Information Toolkit for patients and families affected by rare disease. Information provided includes: what genomics is,
how it might help you or your family, where Queenslanders can get testing and the different kinds of genetic tests that are available.
Although genomic sequencing is a powerful tool, it isn’t always the most appropriate test. This article explains when genomic sequencing will be most useful, and the associated benefits and risks.